ATE490969T1 - Modifizierte transferrin-fusionsproteine - Google Patents
Modifizierte transferrin-fusionsproteineInfo
- Publication number
- ATE490969T1 ATE490969T1 AT02757486T AT02757486T ATE490969T1 AT E490969 T1 ATE490969 T1 AT E490969T1 AT 02757486 T AT02757486 T AT 02757486T AT 02757486 T AT02757486 T AT 02757486T AT E490969 T1 ATE490969 T1 AT E490969T1
- Authority
- AT
- Austria
- Prior art keywords
- fusion proteins
- transferrin fusion
- modified transferrin
- transferrin
- modified
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 3
- 108020001507 fusion proteins Proteins 0.000 title abstract 3
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical class NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 title 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
- 102000004338 Transferrin Human genes 0.000 abstract 2
- 108090000901 Transferrin Proteins 0.000 abstract 2
- 210000002966 serum Anatomy 0.000 abstract 2
- 239000012581 transferrin Substances 0.000 abstract 2
- 102000007238 Transferrin Receptors Human genes 0.000 abstract 1
- 108010033576 Transferrin Receptors Proteins 0.000 abstract 1
- 230000013595 glycosylation Effects 0.000 abstract 1
- 238000006206 glycosylation reaction Methods 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31574501P | 2001-08-30 | 2001-08-30 | |
US33405901P | 2001-11-30 | 2001-11-30 | |
PCT/US2002/027637 WO2003020746A1 (en) | 2001-08-30 | 2002-08-30 | Modified transferrin fusion proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE490969T1 true ATE490969T1 (de) | 2010-12-15 |
Family
ID=26980047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02757486T ATE490969T1 (de) | 2001-08-30 | 2002-08-30 | Modifizierte transferrin-fusionsproteine |
Country Status (17)
Country | Link |
---|---|
US (1) | US20040023334A1 (de) |
EP (1) | EP1427750B1 (de) |
JP (2) | JP2005508623A (de) |
KR (1) | KR20040059490A (de) |
CN (1) | CN1628126A (de) |
AT (1) | ATE490969T1 (de) |
AU (1) | AU2002323501C1 (de) |
BR (1) | BR0212256A (de) |
CA (1) | CA2457520A1 (de) |
DE (1) | DE60238541D1 (de) |
DK (1) | DK1427750T3 (de) |
IL (1) | IL160289A0 (de) |
MX (1) | MXPA04001804A (de) |
NZ (1) | NZ531207A (de) |
RU (1) | RU2004109222A (de) |
WO (1) | WO2003020746A1 (de) |
ZA (1) | ZA200401079B (de) |
Families Citing this family (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8129504B2 (en) | 2001-08-30 | 2012-03-06 | Biorexis Technology, Inc. | Oral delivery of modified transferrin fusion proteins |
US20030226155A1 (en) * | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
MXPA04001804A (es) * | 2001-08-30 | 2005-03-07 | Biorexis Pharmaceutical Corp | Proteinas de fusion de transferrina modificada. |
US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
US20060105387A1 (en) * | 2002-08-30 | 2006-05-18 | Prior Christopher P | Transferrin fusion proteins libraries |
AU2003270010A1 (en) * | 2002-08-30 | 2004-03-19 | Biorexis Pharmaceutical Corporation | Transferrin fusion protein libraries |
WO2004020454A2 (en) * | 2002-08-30 | 2004-03-11 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains |
US7592306B2 (en) * | 2002-12-10 | 2009-09-22 | Agennix, Inc. | Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US20070060512A1 (en) * | 2003-03-04 | 2007-03-15 | Homayoun Sadeghi | Dipeptidyl-peptidase protected protein |
US7379700B2 (en) * | 2003-05-06 | 2008-05-27 | Canon Kabushiki Kaisha | Image reading apparatus with rotatable internal and external guides |
US8105615B2 (en) * | 2003-06-06 | 2012-01-31 | Agennix Incorporated | Lactoferrin as an adjuvant in cancer vaccines |
US20070275871A1 (en) * | 2003-08-28 | 2007-11-29 | Biorexis Technology, Inc. | Epo Mimetic Peptides and Fusion Proteins |
US20060205037A1 (en) * | 2003-08-28 | 2006-09-14 | Homayoun Sadeghi | Modified transferrin fusion proteins |
WO2005054286A2 (en) * | 2003-12-03 | 2005-06-16 | Delta Biotechnology Limited | Interleukin-11 fusion proteins |
WO2006009825A1 (en) * | 2004-06-17 | 2006-01-26 | Virun, Inc. | Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents |
US7183381B2 (en) * | 2004-10-26 | 2007-02-27 | Agennix, Inc. | Composition of lactoferrin related peptides and uses thereof |
CA2610931A1 (en) * | 2005-06-17 | 2006-12-28 | Biorexis Pharmaceutical Corporation | Anchored transferrin fusion protein libraries |
JP4976412B2 (ja) | 2005-12-01 | 2012-07-18 | ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー | エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法 |
AU2007278994B2 (en) | 2006-07-24 | 2013-08-15 | Biorexis Pharmaceutical Corporation | Exendin fusion proteins |
KR100744419B1 (ko) | 2006-08-03 | 2007-07-30 | 동부일렉트로닉스 주식회사 | 반도체 소자 및 반도체 소자의 제조 방법 |
AU2007331195A1 (en) | 2006-12-12 | 2008-06-19 | Biorexis Pharmaceutical Corporation | Transferrin fusion protein libraries |
EP2594583A1 (de) | 2007-08-08 | 2013-05-22 | Novozymes Biopharma DK A/S | Transferrinvarianten und Konjugate |
US8551937B2 (en) * | 2008-05-23 | 2013-10-08 | Daiichi Sankyo Company, Limited | Peptide having an extending action for half-life of object peptide in plasma |
WO2010019718A2 (en) | 2008-08-13 | 2010-02-18 | California Institute Of Technology | Carrier nanoparticles and related compositions, methods and systems |
US20110294988A1 (en) | 2009-02-06 | 2011-12-01 | Novozymes Bio Pharma DK A/S | Purification Process |
EP2216341A1 (de) | 2009-02-10 | 2010-08-11 | Novozymes Biopharma UK Limited | Transferrinvarianten und -konjugate |
CN107188970A (zh) * | 2010-06-04 | 2017-09-22 | 株式会社蒂奥姆生物 | 具有因子vii活性的融合蛋白质 |
KR101853405B1 (ko) * | 2010-10-20 | 2018-05-02 | 주식회사 티움바이오 | 인자 ix 활성을 갖는 융합 단백질 |
AR084020A1 (es) | 2010-11-30 | 2013-04-17 | Genentech Inc | Anticuerpos para el receptor de la barrera hematoencefalica de baja afinidad y sus usos |
WO2012079043A2 (en) * | 2010-12-10 | 2012-06-14 | California Institute Of Technology | Targeting kidney mesangium with nanoparticles of defined diameter |
US9290562B2 (en) | 2011-08-17 | 2016-03-22 | The Regents Of The University Of Colorado | Transferrin-tumstatin fusion protein and methods for producing and using the same |
WO2013072509A1 (en) | 2011-11-16 | 2013-05-23 | Adrenomed Ag | Adrenomedullin assays and methods for determining mature adrenomedullin |
ES2494191T3 (es) | 2011-11-16 | 2014-09-15 | Adrenomed Ag | Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje proteico sin Ig anti-ADM para su utilización en tratamientos |
PL2594587T3 (pl) | 2011-11-16 | 2014-11-28 | Adrenomed Ag | Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zmniejszenia ryzyka śmierci u pacjenta cierpiącego na chorobę przewlekłą lub ostrą lub stan ostry |
SG10202006318TA (en) | 2011-11-16 | 2020-08-28 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition |
PT2780370T (pt) | 2011-11-16 | 2019-10-30 | Adrenomed Ag | Anticorpo anti-adrenomedulina (adm) ou fragmento anticorpo anti-adm ou estrutura de anticorpo anti-adm não ig para utilização na terapia de uma doença aguda ou condição aguda de um paciente para estabilizar a circulação |
HUE042477T2 (hu) | 2011-11-16 | 2019-07-29 | Adrenomed Ag | Anti-adrenomedullin (ADM) ellenanyag vagy anti-ADM ellenanyag-fragmens vagy anti-ADM nem-Ig váz krónikus vagy akut betegségben szenvedõ páciens folyadékegyensúlyának szabályozására |
CN103308689B (zh) | 2012-03-08 | 2017-04-12 | 思芬构技术有限公司 | 用于预测雌性对象中患上癌症的风险或诊断癌症的方法 |
CN103308670B (zh) | 2012-03-08 | 2017-06-09 | 思芬构技术有限公司 | 用于预测对象患糖尿病和/或代谢综合征的风险的方法 |
CN103308673B (zh) | 2012-03-08 | 2017-05-31 | 思芬构技术有限公司 | 用于预测雌性对象中发生心血管事件的风险的方法 |
CA2883711A1 (en) | 2012-09-07 | 2014-03-13 | The Governors Of The University Of Alberta | Methods and compositions for diagnosis of inflammatory liver disease |
EP3361260B1 (de) | 2012-10-02 | 2020-06-10 | sphingotec GmbH | Verfahren zur diagnose oder überwachung der nierenfunktion |
ES2672255T3 (es) * | 2012-12-04 | 2018-06-13 | F. Hoffmann-La Roche Ag | Biomarcadores en la selección de tratamiento para la insuficiencia cardíaca |
JP6430962B2 (ja) | 2013-01-08 | 2018-11-28 | シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 心血管系疾患発症リスクの予測的マーカーとしての成長ホルモンの空腹時レベル |
CN105492459A (zh) * | 2013-02-15 | 2016-04-13 | 高端学术皇家研究会/麦吉尔大学 | 用于治疗糖尿病的修饰的ingap肽 |
JP6408492B2 (ja) | 2013-02-18 | 2018-10-17 | ヴェジェニクス プロプライエタリー リミテッドVegenics Pty Limited | リガンド結合分子およびその使用 |
US9132097B2 (en) | 2013-03-01 | 2015-09-15 | California Institute Of Technology | Nanoparticles stabilized with nitrophenylboronic acid compositions |
US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
WO2014139182A1 (en) | 2013-03-15 | 2014-09-18 | Shenzhen Hightide Biopharmaceutical, Ltd. | Compositions and methods of using islet neogenesis peptides and analogs thereof |
SG10201800309SA (en) | 2013-03-20 | 2018-02-27 | Sphingotec Gmbh | Adrenomedullin to guide therapy of blood pressure decline |
US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
US20160097781A1 (en) | 2014-10-01 | 2016-04-07 | Sphingotec Gmbh | Method for stratifying a female subject for hormone replacement therapy |
CN116869964A (zh) | 2014-12-24 | 2023-10-13 | 耐克西缪恩有限公司 | 用于免疫疗法的纳米颗粒组合物和方法 |
CA2983542A1 (en) | 2015-04-24 | 2016-10-27 | Sphingotec Gmbh | A method for predicting the risk of incidence of chronic kidney disease |
ES2882255T3 (es) | 2015-07-01 | 2021-12-01 | California Inst Of Techn | Sistemas de administración basados en polímeros de ácido múcico catiónicos |
WO2017077382A1 (en) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
EP3377080B1 (de) | 2015-11-19 | 2024-02-14 | Asclepix Therapeutics, LLC | Peptide mit anti-angiogenen, anti-lymphangiogenen und anti-ödematösen eigenschaften und nanopartikelformulierungen |
RU2614141C1 (ru) * | 2015-12-28 | 2017-03-23 | федеральное государственное бюджетное образовательное учреждение высшего образования "Тюменский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Тюменский ГМУ Минздрава России) | Способ прогнозирования парафарингиального абсцесса при остром паратонзиллите |
CN109071632B (zh) | 2016-02-05 | 2022-12-30 | 奥里尼斯生物科学私人有限公司 | 靶向性治疗剂及其用途 |
US11248057B2 (en) | 2016-03-07 | 2022-02-15 | Vib Vzw | CD20 binding single domain antibodies |
MX2018012856A (es) | 2016-04-21 | 2019-07-10 | Sphingotec Therapeutics Gmbh | Metodos para determinar dipeptidil peptidasa 3 y metodos terapeuticos. |
EP3455245A2 (de) | 2016-05-13 | 2019-03-20 | Orionis Biosciences NV | Therapeutisches targeting von nichtzellulären strukturen |
EP3454887B1 (de) | 2016-05-13 | 2021-01-20 | Orionis Biosciences BV | Zielgerichtete mutanten-interferon-beta und verwendungen davon |
MA45493A (fr) | 2016-06-27 | 2019-05-01 | Aicuris Anti Infective Cures Gmbh | Inhibiteurs d'entrée de hcmv. |
MX2019000003A (es) | 2016-07-08 | 2019-08-29 | Sphingotec Gmbh | Adrenomodulina para evaluar la congestión en un individuo con insuficiencia cardiaca aguda. |
KR20190066040A (ko) | 2016-10-04 | 2019-06-12 | 아스클리픽스 테라퓨틱스, 인크. | Tie2 신호전달을 활성화시키기 위한 화합물 및 방법 |
EP3309550A1 (de) | 2016-10-12 | 2018-04-18 | sphingotec GmbH | Verfahren zum nachweis von apolipoprotein e4 |
CA3040802A1 (en) | 2016-10-24 | 2018-05-03 | Orionis Biosciences Nv | Targeted mutant interferon-gamma and uses thereof |
MX2019007107A (es) | 2016-12-16 | 2019-10-21 | Adrenomed Ag | Anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm o supercontigo sin ig anti-adm para su uso en intervencion y terapia de congestion en un paciente con necesidad del mismo. |
EP3339324A1 (de) | 2016-12-22 | 2018-06-27 | sphingotec GmbH | Anti-adrenomedullin (adm)-antikörper oder anti-adm antikörperfragment oder anti-adm-nicht-ig-gerüst zur verwendung in einer intervention und therapie von verstopfung bei einem darauf angewiesenen patienten |
WO2018144999A1 (en) | 2017-02-06 | 2018-08-09 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
WO2018141964A1 (en) | 2017-02-06 | 2018-08-09 | Orionis Biosciences Nv | Targeted chimeric proteins and uses thereof |
EP3580230A1 (de) | 2017-02-07 | 2019-12-18 | VIB vzw | Auf immunzellen gerichtete bispezifische chimäre proteine und verwendungen davon |
EP3631459A1 (de) | 2017-05-30 | 2020-04-08 | SphingoTec GmbH | Verfahren zur diagnose oder überwachung der nierenfunktion oder zur diagnose einer nierendysfunktion |
WO2019006348A1 (en) * | 2017-06-30 | 2019-01-03 | Western University Of Health Sciences | IX-TRANSFERRIN FACTOR FUSION PROTEINS |
WO2019028427A1 (en) | 2017-08-03 | 2019-02-07 | Asclepix Therapeutics, Llc. | METHODS OF IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE TIE2 RECEPTOR |
SG11202002258WA (en) | 2017-09-25 | 2020-04-29 | Adrenomed Ag | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness |
JP2021500548A (ja) | 2017-10-18 | 2021-01-07 | アドレノメト アクチェンゲゼルシャフト | 抗アドレノメデュリン(adm)結合剤での処置下での治療モニタリング |
EP3701266A1 (de) | 2017-10-24 | 2020-09-02 | sphingotec GmbH | Selenoprotein zur vorhersage eines ersten kardiovaskulären ereignisses |
SG11202002594PA (en) | 2017-10-25 | 2020-04-29 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress |
EP3749295A4 (de) | 2018-02-05 | 2022-04-27 | Orionis Biosciences, Inc. | Fibroblastenbindende wirkstoffe und verwendung davon |
AU2019219071A1 (en) | 2018-02-08 | 2020-07-30 | Sphingotec Gmbh | Adrenomedullin (ADM) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia |
EP3569614A1 (de) | 2018-05-18 | 2019-11-20 | Julius-Maximilians-Universität Würzburg | Verbindungen und verfahren zur immobilisierung von myostatin-inhibitoren auf der extrazellulären matrix durch transglutaminase |
EP3586865A1 (de) | 2018-06-21 | 2020-01-01 | Charité - Universitätsmedizin Berlin | Ergänzende anaphylatoxinbindemittel und deren verwendung in der behandlung einer person mit okularer wunde und/oder fibrose |
JP2022514896A (ja) | 2018-12-20 | 2022-02-16 | シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 心不全におけるセレノプロテインp |
CN113557031A (zh) | 2018-12-21 | 2021-10-26 | 4Teen4制药有限公司 | 使用血管紧张肽受体激动剂和/或其前体的治疗的疗法指导和/或疗法监测 |
WO2020168024A1 (en) | 2019-02-15 | 2020-08-20 | Integral Molecular, Inc. | Antibodies comprising a common light chain and uses thereof |
CR20210471A (es) | 2019-02-15 | 2021-12-08 | Integral Molecular Inc | Anticuerpos claudina 6 y usos de los mismos |
EP4014049A1 (de) | 2019-08-15 | 2022-06-22 | sphingotec GmbH | Verfahren zur diagnose oder überwachung der nierenfunktion oder zur diagnose von nierenfunktionsstörungen bei pädiatrischen patienten |
CA3148275A1 (en) | 2019-08-30 | 2021-03-04 | 4TEEN4 Pharmaceuticals GmbH | Therapy guidance and/or therapy monitoring for treatment of shock |
US20220340628A1 (en) * | 2019-09-20 | 2022-10-27 | MVRIX Co., Ltd. | Tag protein for increasing water solubility and heat stability of target protein, and fusion protein comprising same |
EP3871689A1 (de) | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antikörper, die an den freien n-terminus binden, für einen beschleunigten übergang von adm-gly zu bio-adm bei patienten mit einem adm-gly/bio-adm-verhältnis über einem schwellenwert und kombination mit vitamin c |
BR112022016843A2 (pt) | 2020-02-27 | 2022-10-11 | Adrenomed Ag | Ligante antiadrenomedulina (adm) para uso na terapia de pacientes em choque |
CA3168978A1 (en) | 2020-02-27 | 2021-09-02 | Andreas Bergmann | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
AU2021228207A1 (en) | 2020-02-27 | 2022-10-20 | 4TEEN4 Pharmaceuticals GmbH | DPP3 for therapy guidance, monitoring and stratification of nt-ADM antibodies in patients with shock |
EP4121771A1 (de) | 2020-03-16 | 2023-01-25 | AdrenoMed AG | Proadrenomedullin oder fragment davon bei patienten mit coronavirusinfektion und behandlungen mit bindemittel gegen adrenomedullin |
EP3922993A1 (de) | 2020-06-12 | 2021-12-15 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 bei patienten, die mit coronavirus infiziert sind |
AU2021237689A1 (en) | 2020-03-16 | 2022-11-03 | 4TEEN4 Pharmaceuticals GmbH | DPP3 in patients infected with coronavirus |
GB202004514D0 (en) | 2020-03-27 | 2020-05-13 | Inst De Medicina Molecular Joaeo Lobo Antunes | Treatment of Immunosuppressive Cancer |
EP4023218A1 (de) | 2020-12-02 | 2022-07-06 | S-Form Pharma | Kombinationstherapie für patienten mit akuter und/oder anhaltender dyspnoe |
US11180534B1 (en) | 2021-06-04 | 2021-11-23 | Morehouse School Of Medicine | Compositions and methods for treating SARS-CoV-2 infections |
EP4356139A1 (de) | 2021-06-18 | 2024-04-24 | sphingotec GmbH | Verfahren zur vorhersage von sepsis und septischem schock |
EP4363859A1 (de) | 2021-06-29 | 2024-05-08 | berYsol GmbH | Zusammengesetzter biomarker zur identifizierung von selenmangel in einer körperflüssigkeit |
WO2023175035A1 (en) | 2022-03-15 | 2023-09-21 | Adrenomed Ag | Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment |
WO2024008755A1 (en) | 2022-07-04 | 2024-01-11 | Vib Vzw | Blood-cerebrospinal fluid barrier crossing antibodies |
WO2024023368A1 (en) | 2022-07-29 | 2024-02-01 | 4TEEN4 Pharmaceuticals GmbH | Prediction of an increase of dpp3 in a patient with septic shock |
WO2024023369A1 (en) | 2022-07-29 | 2024-02-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
WO2024077118A2 (en) | 2022-10-06 | 2024-04-11 | Bicara Therapeutics Inc. | Multispecific proteins and related methods |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2001A (en) * | 1841-03-12 | Sawmill | ||
US4289689A (en) * | 1980-03-14 | 1981-09-15 | Hoffmann-La Roche Inc. | Preparation of homogeneous human fibroblast interferon |
EP0070906B1 (de) * | 1981-02-04 | 1986-10-15 | Juridical Foundation Japanese Foundation For Cancer Research | Menschliches gen für interferon-beta |
US4816449A (en) * | 1984-08-09 | 1989-03-28 | Immunetech Pharmaceuticals | Immunotherapeutic anti-inflammatory peptide agents |
US5026651A (en) * | 1985-04-25 | 1991-06-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the production of human transferrin |
US5262177A (en) * | 1986-02-07 | 1993-11-16 | Oncogen | Recombinant viruses encoding the human melanoma-associated antigen |
US5260203A (en) * | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US5091513A (en) * | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
PT88641B (pt) | 1987-10-02 | 1993-04-30 | Genentech Inc | Metodo para a preparacao de uma variante de adesao |
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5571691A (en) * | 1989-05-05 | 1996-11-05 | Baylor College Of Medicine | Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms |
FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
US5977307A (en) * | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
US5672683A (en) * | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
US6066469A (en) * | 1990-03-08 | 2000-05-23 | Ferro Dynamics, Inc. | Cloning, expression, and uses of human lactoferrin |
US5723286A (en) * | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
US5986067A (en) * | 1991-02-08 | 1999-11-16 | The University Of Vermont And State Agricultural College | Recombinant transferrins, transferrin half-molecules and mutants thereof |
US5656272A (en) * | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
EP0603187A4 (en) * | 1991-05-31 | 1995-08-30 | Us Health | Human lactoferrin. |
FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
ZA932568B (en) * | 1992-04-24 | 1993-11-12 | Baylor College Midecine A Non | Production of recombinant human lactoferrin |
EP0599303A3 (de) * | 1992-11-27 | 1998-07-29 | Takeda Chemical Industries, Ltd. | Peptide-Konjugate |
US5464933A (en) * | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
US5843882A (en) * | 1995-04-27 | 1998-12-01 | The United States Of America As Represented By The Department Of Health And Human Services | Antiviral proteins and peptides |
US5817789A (en) * | 1995-06-06 | 1998-10-06 | Transkaryotic Therapies, Inc. | Chimeric proteins for use in transport of a selected substance into cells |
US5849293A (en) * | 1996-01-11 | 1998-12-15 | Cornell Research Foundation, Inc. | Use of human transferrin in controlling insulin levels |
US6458924B2 (en) * | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US7235627B2 (en) * | 1996-08-30 | 2007-06-26 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US6258782B1 (en) * | 1998-05-20 | 2001-07-10 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
ES2209885T3 (es) * | 1999-05-17 | 2004-07-01 | Conjuchem, Inc. | Peptidos insulinotropicos de larga duracion. |
US6380362B1 (en) * | 1999-12-23 | 2002-04-30 | Genesis Research & Development Corporation Ltd. | Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use |
US6420346B1 (en) * | 2000-02-07 | 2002-07-16 | Rappaport Family Institute For Research In The Medical Sciences | Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis |
US7176278B2 (en) * | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
MXPA04001804A (es) * | 2001-08-30 | 2005-03-07 | Biorexis Pharmaceutical Corp | Proteinas de fusion de transferrina modificada. |
WO2004020454A2 (en) * | 2002-08-30 | 2004-03-11 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains |
US20060105387A1 (en) * | 2002-08-30 | 2006-05-18 | Prior Christopher P | Transferrin fusion proteins libraries |
US20060205037A1 (en) * | 2003-08-28 | 2006-09-14 | Homayoun Sadeghi | Modified transferrin fusion proteins |
-
2002
- 2002-08-30 MX MXPA04001804A patent/MXPA04001804A/es active IP Right Grant
- 2002-08-30 US US10/231,494 patent/US20040023334A1/en not_active Abandoned
- 2002-08-30 CN CNA028216377A patent/CN1628126A/zh active Pending
- 2002-08-30 RU RU2004109222/13A patent/RU2004109222A/ru not_active Application Discontinuation
- 2002-08-30 KR KR10-2004-7002867A patent/KR20040059490A/ko not_active Application Discontinuation
- 2002-08-30 NZ NZ531207A patent/NZ531207A/en not_active IP Right Cessation
- 2002-08-30 AT AT02757486T patent/ATE490969T1/de not_active IP Right Cessation
- 2002-08-30 BR BR0212256-1A patent/BR0212256A/pt not_active IP Right Cessation
- 2002-08-30 JP JP2003525016A patent/JP2005508623A/ja active Pending
- 2002-08-30 EP EP02757486A patent/EP1427750B1/de not_active Expired - Lifetime
- 2002-08-30 AU AU2002323501A patent/AU2002323501C1/en not_active Ceased
- 2002-08-30 WO PCT/US2002/027637 patent/WO2003020746A1/en active Application Filing
- 2002-08-30 IL IL16028902A patent/IL160289A0/xx unknown
- 2002-08-30 DE DE60238541T patent/DE60238541D1/de not_active Expired - Lifetime
- 2002-08-30 CA CA002457520A patent/CA2457520A1/en active Pending
- 2002-08-30 DK DK02757486.2T patent/DK1427750T3/da active
-
2004
- 2004-02-10 ZA ZA2004/01079A patent/ZA200401079B/en unknown
-
2009
- 2009-08-27 JP JP2009197098A patent/JP2010004891A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
NZ531207A (en) | 2006-08-31 |
BR0212256A (pt) | 2004-08-31 |
DK1427750T3 (da) | 2011-02-14 |
WO2003020746A1 (en) | 2003-03-13 |
CN1628126A (zh) | 2005-06-15 |
IL160289A0 (en) | 2004-07-25 |
ZA200401079B (en) | 2005-05-25 |
RU2004109222A (ru) | 2005-10-20 |
EP1427750A4 (de) | 2006-01-18 |
EP1427750A1 (de) | 2004-06-16 |
AU2002323501B2 (en) | 2009-03-26 |
JP2005508623A (ja) | 2005-04-07 |
US20040023334A1 (en) | 2004-02-05 |
EP1427750B1 (de) | 2010-12-08 |
KR20040059490A (ko) | 2004-07-05 |
DE60238541D1 (de) | 2011-01-20 |
MXPA04001804A (es) | 2005-03-07 |
JP2010004891A (ja) | 2010-01-14 |
CA2457520A1 (en) | 2003-03-13 |
AU2002323501C1 (en) | 2010-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1427750T3 (da) | Modificerede transferrin-fusionsproteiner | |
WO2004020404A3 (en) | Modified transferin-antibody fusion proteins | |
DE60333306D1 (de) | Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy-terminalen domänen | |
WO2004020405A3 (en) | Modified transferrin fusion proteins | |
WO2007047504A3 (en) | Natriuretic peptide modified transferrin fusion proteins | |
ATE316982T1 (de) | Mehrere zytokin-antikörper komplexen | |
DK1088084T3 (da) | Erythropoietin analog-humant serumalbumin fusionsprotein | |
PL369741A1 (en) | Immunocytokines with modulated selectivity | |
CY1105895T1 (el) | Χιμαιρικη πρωτεϊνη διαλυτου υποδοχεα/συνδετη ιντepλευκινης-6, αναλογα και αυτης και χρησεις αυτης | |
DE50012863D1 (de) | Strukturprotein von adeno-assoziiertem virus mit veränderten chromatographischen eigenschaften | |
MXPA02004666A (es) | Gelatinas recombinantes. | |
WO2002079232A3 (en) | Reducing the immunogenicity of fusion proteins | |
WO2004019872A3 (en) | Oral delivery of modified transferrin fusion proteins | |
DE60330680D1 (de) | Transferrin-fusionsproteinbibliotheken | |
DE50307984D1 (de) | Streptavidin-Bindungspeptid | |
WO2006049983A3 (en) | Peptide yy modified transferrin fusion proteins | |
ATE550345T1 (de) | Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren | |
BR0212287A (pt) | Proteìna de ligação caspase-8, sua preparação e uso | |
WO2008021412A3 (en) | Interferon beta and transferrin fusion proteins | |
HK1082510A1 (en) | Promoter to il-18bp, its preparation and use | |
WO2001002429A3 (en) | Angiopoietin-6 and uses thereof | |
ATE325873T1 (de) | Androgenrezeptor-komplex assoziiertes protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |